TSFAE19a:	Subjects With Treatment-emergent Adverse Events by Male-specific FDA Medical Query (Narrow) and Preferred Term; Male-specific Safety Analysis Set (Study jjcs - core)						
 	Active Study Agent 	Active Study Agent 	 	Risk Difference (%) (95% CI) 	Risk Difference (%) (95% CI) 	
OCMQ (Narrow) 	Xanomeline High Dose 	Xanomeline Low Dose 	Placebo 	Xanomeline High Dose vs Placebo 	Xanomeline Low Dose vs Placebo 	
  Preferred Term, n (%) 	N=29 	N=34 	N=23 	  	  	
Erectile Dysfunction 	1 (3.4%) 	0 	1 (4.3%) 	-0.9 (-11.6, 9.8) 	-4.3 (-12.7, 4.0) 	
ERECTILE DYSFUNCTION 	1 (3.4%) 	0 	1 (4.3%) 	-0.9 (-11.6, 9.8) 	-4.3 (-12.7, 4.0) 	
 	 	 	 	 	 	
Gynecomastia 	0 	0 	0 	0.0 (0.0, 0.0) 	0.0 (0.0, 0.0) 	

Key: FMQ=FDA Medical Query 	
Key: FMQ=FDA Medical Query	
Key: FMQ=FDA Medical Query	
Key: FMQ=FDA Medical Query	
Key: FMQ=FDA Medical Query	
Key: FMQ=FDA Medical Query	
Note: Adverse events are coded using MedDRA version 26.0. 	: Adverse events are coded using MedDRA version 26.	: Adverse events are coded using MedDRA version 26.	: Adverse events are coded using MedDRA version 26.	: Adverse events are coded using MedDRA version 26.	: Adverse events are coded using MedDRA version 26.